中晚期原发性肝癌内科治疗的研究进展

摘要
图/表
参考文献(31)
相关文章 (15)

全文: PDF (0 KB) HTML (39 KB)
输出: BibTeX | EndNote (RIS)

摘要原发性肝癌是临床最常见、死亡率最高的恶性肿瘤之一，确诊时多为中晚期，内科治疗是中晚期患者的主要治疗手段。生物靶向治疗和化疗是恶性肿瘤常用的内科治疗方法。近年来，生物靶向治疗与化疗联合治疗肿瘤已成为肿瘤临床研究的热点。本文就中晚期原发性肝癌内科治疗中的生物靶向治疗和化疗进行综述。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	张青
	沈永奇
	韩朝稳
	陈超庭

关键词 ：原发性肝癌, 生物靶向治疗, 化疗, 内科治疗

Abstract：Primary liver cancer(PLC)is one of the most common malignant tumors with the highest mortality.Most of the patients are diagnosed at advanced stages.Medical treatment is the main treatment for middle and advanced stage patients.In recent years,the combination of biological targeting therapy and chemotherapy has become a hot topic in cancer clinical research.Biologically-targeted therapy and chemotherapy are commonly used in the internal medicine treatment of malignant tumor.In recent years,the combination of biologically-targeted therapy and chemotherapy in the treatment of tumor has become a hot spot in the clinical research of tumor.This article reviews the biological targeting therapy and chemotherapy in the medical treatment of middle and advanced stage PLC.

Key words： Primary liver cancer Biological targeted therapy Chemotherapy Medical treatment

基金资助:广西壮族自治区卫生和计划生育委员会自筹经费科研课题（Z20180139）

作者简介: 张青（1983-），女，本科，主管药师，研究方向：临床药学

引用本文:

张青；沈永奇；韩朝稳；陈超庭. 中晚期原发性肝癌内科治疗的研究进展[J]. 中国当代医药, 2019, 26(17): 17-20.
ZHANG Qing； SHEN Yong-qi； HAN Chao-wen； CHEN Chao-ting. Research progress of medical treatment of advanced primary liver cancer. 中国当代医药, 2019, 26(17): 17-20.

链接本文:

http://dangdaiyiyao.com/CN/ 或 http://dangdaiyiyao.com/CN/Y2019/V26/I17/17

[2]	郭列平.节律性化疗在晚期肝细胞肝癌中的应用进展[J].中国肿瘤临床，2017，44（18）：948-952.
[3]	Chen W，Zheng R，Baade PD，et al.Cancer statistics in China，2015[J].CA Cancer J Clin，2016，66（2）：115-132.
[1]	Global Burden of Disease Cancer Collaboration，Fitzmaurice C，Allen C，et al.Global，regional，and national cancer incidence，mortality，years of life lost，years lived with disability，and disability-adjusted life-years for 32 cancer groups，1990 to 2015：a systematic analysis for the global burden of disease study[J].JAMA Oncol，2017，3（4）：524-548.
[4]	Wallce MC，Preen D，Gary PE，et al.The evolving epidemiology of hepatocellular carcinoma：a global perspective[J].Exp Rev Gasteoen Hepatol，2015，9（6）：765-779.
[5]	Li YC，Zhao L，Wu JP，et al.Cytokine-induced killer cell infusion combined with conventional treatments produced better prognosis for hepatocellular carcinoma patients with barcelona clinic liver cancer B or earlier stage：a systematic review and meta-analysis[J].Cytotherapy，2016，18（12）：1525-1531.
[6]	Bupathi M，Kaseb A，Meric-Bernstam F，et al.Hepatocellular carcinoma：where there is unmet need[J].Mol Oncol，2015，9（8）：1501-1509.
[7]	Llovet JM，Ricci S，Mazzaferro V，et al.Sorafenib in advanced hepatocellular carcinoma[J].N Engl J Med，2008，359（4）：378-390．
[8]	Cheng AL，Kang YK，Chen Z，et al.Efficacy and safety ofsorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma：a phase Ⅲ randomised，doubleblind，placebo-controlled trial retrieved no results[J].Lancet Oncol，2009，10（1）：25-34．
[9]	Cheng AL，Kang YK，Lin DY，et al.Sunitinib versus sorafenib in advanced hepatocellular cancer：Results of a randomized phase Ⅲ trial[J].J Clin Oncol，2013，31（32）：4067-4075.
[10]	Jonker DJ，Rosen LS，Sawyer MB，et al.A phase Ⅰ study to determine the safety，pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor，brivanib，in patients with advanced or metastatic solid tumors[J].Ann Oncol，2011，22（6）：1413-1419.
[11]	Finn RS，Kang YK，Mulcahy M，et al.Phase Ⅱ，open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma[J].Clin Cancer Res，2012，18（7）：2090-2098.
[12]	Johnson P，Qin S，Park JW，et al.Brivanib versus sorafenib as first-line therapy in patients with unresectable，advanced hepatocellular carcinoma：Results from the phase 3 BRISKFL study hepatoloy[J].Clin Onocl，2013，31（28）：3517-3524.
[13]	Llovet JM，Decaens T，Raoul JL，et al.Brivanib versus placeboin patients with advanced hepatocellular carcinoma（HCC） who failed or were intolerant to sorafenib：Results from the phase 3 BRISK-PS study[J].J Hepatol，2012，56（Suppl 2）：S549.
[14]	Zhu AX，Finn RS，Mulcahy M，et al.A phaseⅡ and biomarker of studay ramucirumab，a human monoclonal antibody targeting the VEGF receptor-2，as first-line monotherapy in patients with advanced hepatocellular cancer[J].Clin Cancer Res，2013，19（23）：6614-6623.
[15]	ZhuAX，Park ZJ，Ryoo BY，et al.Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib （REACH）：a randomised，double-blind，multicentre，phase 3 trial[J].Lancet Oncol，2015，16（7）：859-870.
[16]	Melero I，Sangro B，Yau TC，et al．Safety and antitumor activity of nivolumab （nivo） in patients （pts） with advanced hepatocellular carcinoma （HCC）：Interim analysis of dose-expansion cohorts from the phase 1/2 Check Mate-040 study[J]．J Clin Oncol，2016，34（Suppl 15）：abstr4078．
[17]	Liu L，Yu H，Huang L，et al.Progression-free survival as a surrogate endpoint for overall survival in patients with third-line or later-line chemotherapy for advanced gastric cancer[J].Oncotarget Ther，2015，8：921-928.
[18]	姜增凯，叶晓歌，陈琴华.阿帕替尼对肝癌细胞增殖和迁移能力的影响研究[J].中国临床药理学杂志，2016，32（15）：1422-1424.
[19]	Qin S.Apatinib in Chinese patients with advanced hepatocellular carcinoma：a phase Ⅱ randomized，open-label trial[J].J Clin Oncol，2014，32（15 Suppl）：4019.
[20]	Chen P，Cui YL，Zhu XL，et al.Apatinib is effective for treatment of advanced hepatocellular carcinoma[J].Oncotarget，2017，8（62）：105 596-105 605.
[21]	李威，满文玲，郭欢庆，等.TACE联合甲磺酸阿帕替尼治疗中晚期肝癌的临床研究[J].肿瘤药学，2017，7（1）：74-78.
[22]	杨斌，谢辉，王春平，等.安罗替尼对人肝内胆管细胞癌细胞系HCCC-9810作用研究[J].中国医药导刊，2017，19（12）：1389-1391.
[23]	Qin S，Bai Y，Lim HY，et al.Randomized，multicenter，openlabel study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia[J].J Clin Oncol，2013，31：3501-3508.
[24]	卫生和计划生育委员会医政医管局.原发性肝癌诊疗规范（2017年版）[J].中华消化外科杂志，2017，16（7）：635-647.
[25]	刘琳，郑英慧，韩力，等.含奥沙利铂系统化疗方案治疗晚期原发性肝癌有效性和安全性的前瞻性研究荟萃分析[J].临床肿瘤学杂志，2015，20（9）：769-779.
[27]	沈永奇，黄军，陈超庭，等.雷替曲塞联合奥沙利铂与FOLFOX4方案治疗中晚期原发性肝癌的疗效评价[J]，实用临床医药杂志，2017，21（7）：39-42.
[28]	陈超庭，沈永奇，黄汉生，等.奥沙利铂单药治疗Child-Pugh B级中晚期肝癌的临床研究[J].中国热带医学，2018，18（5）：489-492，499.
[31]	彭雨.索拉非尼联合FOLFOX4化疗治疗晚期原发性肝癌的前瞻性临床研究[J].慢性病学杂志，2018，19（5）：525-527.
[26]	BrandiG，deRosaF，AgostiniV，etal.Metronomiccapecitabine in advanced hepatocellular carcinoma patients：a phase Ⅱstudy[J].Oncologist，2013，18（12）：1256-1257.
[29]	Zhu AX，Blaszkowsky LS，Ryan DP，et al.Phase Ⅱ study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma[J].J Clin Oncol，2006，24（12）：1898-1903.
[30]	Ying L，Han Y，Xu S，et al.First-line gemcitabine and oxaliplatin （GEMOX） plus sorafenib，followed by sorafenib as maintenance therapy，for patients with advanced hepatocellular carcinoma：a preliminary study[J].Int J Clin Oncol，2015，20（5）：952-959.